C
Chong-Rui Xu
Researcher at Guangdong General Hospital
Publications - 83
Citations - 3837
Chong-Rui Xu is an academic researcher from Guangdong General Hospital. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 19, co-authored 62 publications receiving 3009 citations. Previous affiliations of Chong-Rui Xu include Peking Union Medical College & Sun Yat-sen University.
Papers
More filters
Journal ArticleDOI
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu,Caicun Zhou,Chengping Hu,Jifeng Feng,Shun Lu,Yunchao Huang,Wei Li,Mei Hou,Jian Hua Shi,Kye Young Lee,Chong-Rui Xu,Dan Massey,MI-Young Kim,Yang Shi,Sarayut Lucien Geater +14 more
TL;DR: Afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-positive advanced lung NSCLC and should be considered as a first-line treatment option for this patient population.
Journal ArticleDOI
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong-Yi Dong,Jia-Tao Zhang,Si-Yang Liu,Jian Su,Chao Zhang,Zhi Xie,Qing Zhou,Hai-Yan Tu,Chong-Rui Xu,Li-Xu Yan,Y. Li,Wen-Zhao Zhong,Yi-Long Wu +12 more
TL;DR: Evidence is provided of a correlation between EGFR mutations and an uninflamed tumor microenvironment with immunological tolerance and weak immunogenicity, which caused an inferior response to PD-1 blockade in NSCLCs.
Journal ArticleDOI
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Qing Zhou,Xu-Chao Zhang,Zhi-Hong Chen,Xiao-Lu Yin,Jin-Ji Yang,Chong-Rui Xu,Hong-Hong Yan,Hua-Jun Chen,Jian Su,Wen-Zhao Zhong,Xue-Ning Yang,She-Juan An,Bin-Chao Wang,Yi-Sheng Huang,Zhen Wang,Yi-Long Wu +15 more
TL;DR: The relative EGFR mutation abundance could predict benefit from EGFR-TKI treatment for advanced NSCLC and the difference between patients with high and low abundances of EGFR mutations was not significant regarding ORR and OS.
Journal ArticleDOI
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Y.-S. Li,Ben-Yuan Jiang,J.-J. Yang,X. Zhang,Zhou Zhang,J.-Y. Ye,Wen-Zhao Zhong,Hai-Yan Tu,H. Chen,Zhen Wang,Chong-Rui Xu,Bin-Chao Wang,H.J. Du,S. Chuai,Han Han-Zhang,Jian Su,Qing Zhou,X.N. Yang,W.B. Guo,Hong-Hong Yan,Y. H. Liu,L.X. Yan,B. Huang,M.M. Zheng,Yi-Long Wu +24 more
TL;DR: CSF cfDNA could reveal the unique genetic profiles of LM and should be considered as the most representative liquid biopsy medium for LM in EGFR-mutant NSCLC.
Journal ArticleDOI
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer
Jin-Ji Yang,Hua-Jun Chen,Hong-Hong Yan,Xu-Chao Zhang,Qing Zhou,Jian Su,Zhen Wang,Chong-Rui Xu,Yi-Sheng Huang,Bin-Chao Wang,Xue-Ning Yang,Wen-Zhao Zhong,Qiang Nie,Ri-Qiang Liao,Ben-Yuan Jiang,Song Dong,Yi-Long Wu +16 more
TL;DR: Clinical modes of EGFR-TKI failure could favor strategies for subsequent treatment and predicting a survival benefit in advanced NSCLC.